Cat. No. | Product name | CAS No. |
DC8728 |
CH5424802(Alectinib HCl)
Featured
CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation. |
1256589-74-8 |
DC10467 |
CHMFL-BMX-078
Featured
CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM. |
1808288-51-8 |
DC7668 |
CL-387785
Featured
CL-387785(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR with IC50 of 370+/-120 pM; is able to overcome resistance caused by the T790M mutation on a functional level. |
194423-06-8 |
DC8651 |
CO-1686 hydrobromide
Featured
CO-1686 hydrobromide is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M (IC50=21 nM). |
1446700-26-0 |
DC7106 |
Rociletinib (CO-1686)
Featured
CO-1686 is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M(IC50=21 nM). |
1374640-70-6 |
DC7389 |
CP-673451
Featured
CP 673451 is a selective inhibitor of PDGFRα/β with IC50 of 10 nM/1 nM, exhibits >450-fold selectivity over other angiogenic receptors, has antiangiogenic and antitumor activity. |
343787-29-1 |
DC4132 |
CP-547632
Featured
CP-547632 is as a potent inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases (IC50 11 and 9 nM, respectively). |
252003-65-9 |
DC8892 |
CP724714
CP-724714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc in cell-free assays. Phase 2. |
537705-08-1 |
DC5159 |
CP-868596 (Crenolanib)
Featured
Crenolanib (CP-868596) is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB |
670220-88-9 |
DC2100 |
Dasatinib (BMS-354825)
Featured
Dasatinib (BMS-354825, Sprycel) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.5 nM and 79 nM, respectively. |
302962-49-8 |
DC5041 |
DCC-2036 (Rebastinib)
Featured
DCC-2036 is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1/2. |
1020172-07-9 |
DC9585 |
c-Kit-IN-1(DCC-2618)
Featured
DCC-2618 is a small molecule inhibitor of c-Kit and PDGFR with IC50s of 6 nM/30 nM/13 nM for c-Kit/PDGFRα/PDGFRβ respectively. |
1225278-16-9 |
DC10996 |
DDR inhibitor X
Featured
DDR inhibitor X is a potent discoidin domain receptor (DDR) inhibitor with IC50 of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM.. |
1644069-80-6 |
DC7695 |
Defactinib (VS-6063, PF-04554878)
Featured
Defactinib is a potent, selective, and orally active FAK inhibitor with demonstrated tolerability and preliminary clinical activity working as a single agent as well as in combination with paclitaxel. |
1073154-85-4 |
DC10100 |
Defactinib hydrochloride
Featured
Defactinib is a potent, selective, and orally active FAK inhibitor with demonstrated tolerability and preliminary clinical activity working as a single agent as well as in combination with paclitaxel. |
1073160-26-5 |
DC10559 |
Derazantinib (ARQ 087)
Featured
Derazantinib (Derazantinib) is an ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively. |
1234356-69-4 |
DC10060 |
Dianilinopyrimidine_01(CZC8004)
Featured
Dianilinopyrimidine_01 is a Pan Tyrosine kinase inhibitor. |
916603-07-1 |
DC4157 |
Dovitinib (TKI258, CHIR258)
Featured
Dovitinib (TKI258, CHIR258) is a novel multi-target inhibitor for Flt3, c-Kit, FGFR1/3, VEGFR1/2/3, PDGFRα/β with IC50 of 1 nM, 2 nM, 8 nM/9 nM and 10 nM/13 nM/8 nM, 210 nM/27 nM respectively. |
405169-16-6 |
DC3141 |
Dovitinib (TKI258) Lactate
Featured
Dovitinib (TKI258, CHIR258) is a novel multi-target inhibitor for Flt3, c-Kit, FGFR1/3, VEGFR1/2/3, PDGFRα/β with IC50 of 1 nM, 2 nM, 8 nM/9 nM and 10 nM/13 nM/8 nM, 210 nM/27 nM respectively. |
915769-50-5 |
DC10313 |
Dovitinib lactate
Dovitinib(CHIR-258; TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) with an IC50 of 5 nM. |
692737-80-7 |
DC11175 |
Dual DDR1 and DDR2 inhibitor 5n
Dual DDR1 and DDR2 inhibitor 5n is a highly potent, selective, dual Discoidin domain receptor DDR1 and DDR2 inhibitor with Kd of 7.9 and 8.0 nM, IC50 of 9.4 and 20.4 nM, repectively. |
2241813-33-0 |
DC7128 |
Lucitanib(E3810)
Featured
E-3810 is a novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity. |
1058137-23-7 |